HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Nasal NK-cell lymphoma].

Abstract
A 75-year-old man was admitted to our hospital on June 1st, 1993, because of nasal obstruction, epistaxis, fever, night sweats and weight loss. Examination disclosed a 2-cm white necrotic mass in the nasal septum, and a biopsy disclosed non-Hodgkin's lymphoma, diffuse, mixed-type. Imprint smears showed cytoplasmic azurophilic granules in the tumor cells. Dense granules were demonstrated by electron microscopy. The tumor cells were CD1-2+3-4-7+8-16+56+57-, and T cell receptor genes were in germline configuration. NK activity against K562 was strongly positive. Based on morphologic, phenotypic, immunogenotypic, and cytotoxic findings, the tumor cells seemed to be derived from activated NK cells. Because the tumor cells were positive for the EB virus and CD21 antigen, EB virus seemed to have infected CD21-positive NK cells and transformed them. MDR P-glycoprotein was also positive. This finding may explain why nasal lymphomas are resistant to chemotherapy and have a poor prognosis.
AuthorsJ Fukuda, T Yoshihara, Y Arai, T Kaneko, H Zheng, S Mori, M Aoyama, M Masuda, T Motoji, K Oshimi
Journal[Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 35 Issue 6 Pg. 588-92 (Jun 1994) ISSN: 0485-1439 [Print] Japan
PMID8078194 (Publication Type: Case Reports, English Abstract, Journal Article)
Topics
  • Cell Transformation, Viral
  • Herpesvirus 4, Human
  • Humans
  • Killer Cells, Natural (immunology)
  • Lymphoma, Non-Hodgkin (immunology, pathology)
  • Male
  • Middle Aged
  • Nose Neoplasms (immunology, pathology)
  • Prognosis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: